Anti-Human IL-6R (Tocilizumab)

Anti-Human IL-6R (Tocilizumab)

Product No.: I-1240

- -
- -
Product No.I-1240
Clone
RG-1569
Target
IL-6R
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
IL6R, CD126, IL6RA
Isotype
Human IgG1κ
Applications
ELISA
,
FA
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Human
Expression Host
HEK-293 Cells
FC Effector Activity
Active
Immunogen
Humanized antibody derived from mouse clone PM-1
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
FA,
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tocilizumab. Tocilizumab activity is directed against IL-6R.
Background
IL-6 is a pleiotropic cytokine that promotes B cell and T cell proliferation and differentiation and is also involved in the inflammatory response 1 . In the ‘classic’ signaling paradigm, IL-6 binds to its membrane bound receptor IL-6R to initiate intracellular signaling pathways 2. Alternatively, in ‘trans-signaling’, IL-6 binds to a soluble form of IL-6R. In both events, a complex set of interactions with membrane-bound or soluble β-receptor glycoprotein 130 (gp130) modulates the downstream signaling pathways. Additionally, IL-6 plays an inflammatory role in autoimmune diseases 3 and high IL-6 levels are a feature of cytokine storm and cytokine release syndrome during COVID-19 infection1 . IL-6 signaling can be inhibited by antibodies directed against IL-6R 3.

Tocilizumab is the first IL-6R inhibitor3 . It competitively inhibits the binding of IL-6 to both soluble and membrane bound IL-6R 3, 4, and thereby prevents IL-6 signal transduction to inflammatory mediators that summon B and T cells 3.

Tocilizumab is a chimeric murine-human antibody engineered by CDR grafting of the antigen binding regions of murine antihuman IL-6R antibody PM-1 to the human IgG1 framework 3, 5. Tocilizumab binds to the IL-6 binding site and neutralizes IL-6 activity 5, 6, 7. Tocilizumab has been studied for the treatment of many autoimmune diseases including rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease, and Crohn’s disease 7 as well as for the treatment of severe COVID-19 1 .
Antigen Distribution
IL-6R is expressed on hepatocytes and certain subpopulations of leukocytes.
Ligand/Receptor
IL-6 & ciliary neurotrophic factor
NCBI Gene Bank ID
UniProt.org
Research Area
Biosimilars
.
Cancer
.
Immuno-Oncology
.
Immunology

References & Citations

1 Cortegiani A, Ippolito M, Greco M, et al. Pulmonology. 27(1):52-66. 2021.
2 Wolf J, Rose-John S, Garbers C. Cytokine. 70(1):11-20. 2014.
3 Sebba A. Am J Health Syst Pharm. 65(15):1413-1418. 2008.
4 Mihara M, Kasutani K, Okazaki M, et al. Int Immunopharmacol. 5(12):1731-1740. 2005.
5 Sato K, Tsuchiya M, Saldanha J, et al. Cancer Res. 53(4):851-856. 1993.
6 Tsunenari T, Koishihara Y, Nakamura A, et al. Blood. 90(6):2437-2444. 1997.
7 Yao X, Huang J, Zhong H, et al. Pharmacol Ther. 141(2):125-139. 2014.
Indirect Elisa Protocol
FA
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.